10 studies found for:    Open Studies | "Carcinoma, Merkel Cell"
Show Display Options
Rank Status Study
1 Recruiting MSB0010718C in Subjects With Merkel Cell Carcinoma
Condition: Carcinoma, Merkel Cell
Intervention: Drug: MSB0010718C
2 Recruiting Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Conditions: Merkel Cell Carcinoma;   Skin Cancer
Intervention: Drug: Cabozantinib
3 Recruiting A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Intervention: Biological: GLA-SE
4 Recruiting F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Interventions: Drug: Arm A: F16IL2 in combination with paclitaxel;   Drug: Arm B: Paclitaxel
5 Recruiting Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Condition: Merkel Cell Carcinoma
Intervention: Drug: Ipilimumab
6 Recruiting Dose Escalation Study to Investigate Safety, PK and Anti-tumor Activity of Pasireotide in Patients With Metastatic Melanoma or Merkel Cell Carcinoma
Condition: Metastatic Melanoma and Merkel Cell Carcinoma
Intervention: Drug: Pasireotide sub-cutaneous formulation
7 Recruiting Merkel Positron Emission Tomography (PET) Protocol
Condition: Merkel Cell Carcinoma
Interventions: Drug: Carboplatin;   Drug: Etoposide;   Radiation: Radiotherapy
8 Recruiting Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Radiation: radiation therapy;   Biological: recombinant interferon beta;   Biological: MCPyV TAg-specific polyclonal autologous CD8-positive T cell vaccine;   Biological: aldesleukin;   Other: laboratory biomarker analysis
9 Recruiting Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage I Neuroendocrine Carcinoma of the Skin;   Stage II Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Biological: interleukin-12 gene;   Biological: electroporation-mediated plasmid DNA vaccine therapy;   Other: laboratory biomarker analysis
10 Recruiting Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Neuroendocrine Carcinoma of the Skin;   Regional Gastrointestinal Carcinoid Tumor;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: pazopanib hydrochloride;   Other: placebo;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years